Umbilical Cord–Derived Mesenchymal Stromal Cells For Prevention of Chronic Graft-vs-Host Disease

To the Editor The study conducted by Huang et al is remarkable, but certain critical details related to umbilical cord (UC)–derived mesenchymal stromal cells (MSCs) are notably missing: whether the fetal end or maternal end of UC was used for the isolation of MSCs, the specific passage number, the serum substitute used in the culture media, whether they were pooled from different UCs or not, timing of cryopreservation and freeze-thaw cycles of UC-MSCs affects their immune-suppressive activity, which could be a potential source of variability in its activity. Again, the status of senescence-related proteins (p53, p21) has not been reported in UC-MSCs as it has been reported that wild-type MSCs become senescent after a short-term in vitro culture.

Leggi
Luglio 2024

Magnetic Seizure Therapy vs Electroconvulsive Therapy for Major Depressive Episode

To the Editor Electroconvulsive therapy (ECT) is widely regarded as the most effective short-term treatment for major depressive episodes, including treatment-resistant depression (TRD). Deng et al recently reported in JAMA Psychiatry the Clinical Outcomes of Magnetic Seizure Therapy (MST) vs ECT for Major Depressive Episode study, finding that the efficacy of ECT and MST were “indistinguishable.” Expanding the interventions considered effective in TRD is welcome, given the dire need. However, the ECT remission rate after short-term treatment was exceptionally low, limiting confidence in the validity and/or generalizability of the findings.

Leggi
Luglio 2024

Umbilical Cord–Derived Mesenchymal Stromal Cells For Prevention of Chronic Graft-vs-Host Disease—Reply

In Reply Mesenchymal stem cells (MSCs) are immunological regulatory cells that have been increasingly used in hematopoietic stem cell transplant (HSCT); however, there are some aspects that remain optimization and warrant further investigation. We are grateful for the acknowledgment and validation from Mendiratta et al on our article. We are now offering responses to the comments.

Leggi
Luglio 2024